BioCentury | Apr 24, 2018
Politics & Policy

Carter introduces 340B transparency bill

...titled the 340B Optimization Act, seeks to provide a better understanding of patient makeup of DHS...
BioCentury | Dec 3, 2012
Company News

Bavarian Nordic, NIH, U.S. Department of Homeland Security infectious news

...the advanced development of a MVA-BN-based human vaccine against the Marburg virus hemorrhagic fever. The DHS...
BioCentury | Sep 12, 2011
Politics, Policy & Law

Biodefense report card

...BARDA's projection that it will have countermeasures for all of the bioterrorism threats identified by DHS...
BioCentury | Jun 9, 2011
Distillery Therapeutics

Indication: Cancer

...affiliation as above e-mail: yfxu@ecust.edu.cn Contact: Hua Xie, Chinese Academy of Sciences, Shanghai, China e-mail: hxie@jding.dhs.org BC...
BioCentury | Jun 10, 2010
Cover Story

Unique pathway in diabetes

...nowhere else in nature. This conversion requires the sequential activity of two enzymes: deoxyhypusine synthase ( DHPS...
...EIF5A's effects on inflammation. The team found that a commercially available small molecule inhibitor of DHPS...
...iNOS, glucose response and insulin secretion in cultured b cells. Diabetic mice treated with the DHPS...
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Endocrine disease

...Endocrine disease Diabetes Deoxyhypusine synthase (DHPS); eukaryotic translation initiation factor 5A (EIF5A) A study in mice suggests...
...be useful for treating type 1 diabetes. Hypusine is an unconventional amino acid made by DHPS...
...of type 1 diabetes, small interfering RNA knockdown of Eif5a or small molecule inhibition of Dhps...
BioCentury | Sep 24, 2007
Company News

Isis Pharmaceuticals, U.S. Department of Defense, U.S. Department of Homeland Security infectious, diagnostic news

...ISIS's Ibis Biosciences Inc. subsidiary received three contracts from DHS totaling $3.3 million to develop methods...
BioCentury | Sep 10, 2007
Company News

GenVec, U.S. Department of Homeland Security veterinary news

DHS exercised the first of two annual renewal options under a three-year contract with GNVC to develop and manufacture an adenovector-based vaccine to prevent foot-and-mouth disease, which affects animals such as cattle and swine (see...
BioCentury | Feb 5, 2007
Company News

GenVec, U.S. Department of Homeland Security veterinary, infectious news

...GNVC signed a three-year contract with the DHS to develop and manufacture an adenovector-based vaccine to...
...to $6 million the first year and is eligible for an additional $9 million if DHS...
...annual renewal options. GNVC will develop, produce and obtain regulatory approval for the vaccine, which DHS...
BioCentury | Jul 13, 2006
Politics & Policy

Senate backs personal importation

...Canada for personal use. The bill, which was an amendment to Department of Homeland Security (DHS...
...Bill Nelson (D-Fla.), could be modified or deleted when House and Senate versions of the DHS...
Items per page:
1 - 10 of 14